GRALGRALHealthcare · Diagnostics & Research

GRAL Stock Forecast: GRAIL, Inc. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$116
−4.59% on the day

The 10 Wall Street analysts covering GRAIL, Inc. hold a median 12-month price target of $150 — +29.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 14 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$5.2B
Ticker Nerd rank
35/ 100
Median analyst target
$150
Analysts covering
10
Revenue$44.7M+25.7% y/y
Operating income−$148.4M
Net income−$110.2M
Free cash flow−$81.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−4.7%
1M
−17.5%
YTD
+35.3%
1Y
+39.2%
From 52W high
−27.1%
From 52W low
+169.1%
$43
$159
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

GRAL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GRAIL, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Nov 2026
35/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
91
Revisions
69
Accruals
61
Growth
45
Value
31
Quality
25
Issuance
23
Size
22
Volatility
12

Momentum (91): The shares have been drifting up relative to others.

Volatility (12): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GRAL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GRAL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$100$150$200Jan 26Apr 26Jul 26Oct 26GRALHigh $175Median $150Low $100

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
5 Buy5 Hold0 Sell
Low $100Median $150High $175

The green dot is the last close — the median target sits +29.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
10 Nov 2026Piper SandlerMaintainsNeutral$74 → $130
5 Nov 2026RBC CapitalMaintainsSector Perform$84 → $100
13 Oct 2026Morgan StanleyMaintainsEqual-Weight—
13 Oct 2026Morgan StanleyMaintainsEqual-Weight$60 → $120
13 Oct 2026TD CowenMaintainsBuy—
13 Oct 2026TD CowenMaintainsBuy$88 → $180
2 Oct 2026UBSMaintainsBuy—
2 Oct 2026UBSMaintainsBuy$105 → $175
1 Oct 2026GuggenheimMaintainsBuy—
1 Oct 2026GuggenheimMaintainsBuy$75 → $155
28 Sept 2026Canaccord GenuityMaintainsBuy—
28 Sept 2026Canaccord GenuityMaintainsBuy$80 → $150
25 Sept 2026MizuhoMaintainsNeutral—
25 Sept 2026MizuhoMaintainsNeutral$65 → $100
22 Sept 2026BairdMaintainsOutperform—
22 Sept 2026BairdMaintainsOutperform$96 → $118
17 Sept 2026RBC CapitalInitiatesSector Perform$84
17 Sept 2026RBC CapitalInitiatesSector Perform—
9 Sept 2026UBSInitiatesBuy$105
9 Sept 2026UBSInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

GRAL appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GRAL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, GRAIL, Inc. returned +39.2% against +13.5% for the S&P 500, dividends included.

GRAL vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26GRALS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GRAL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

GRAIL, Inc. (GRAL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.4×

Cheaper than 94% of US stocks

Price / sales
31.3×

Cheaper than 6% of US stocks

Price / book
2.1×

Cheaper than 40% of US stocks

EV / EBITDA
−11.3×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
3.7%

Higher than 37% of US stocks

Earnings growth (YoY)
25.7%

Higher than 64% of US stocks

Gross margin
−28.1%

Higher than 3% of US stocks

Operating margin
−332.0%

Higher than 8% of US stocks

Net margin
−243.8%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−17.3%

Higher than 32% of US stocks

Return on assets
−13.0%

Higher than 24% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GRAIL, Inc. (GRAL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GRAIL, Inc. has a market value of $5.2B and an enterprise value of $4.5B.

  • Revenue in the twelve months to 30 June 2026: $165.3M. The latest quarter grew 3.7% year on year.

  • Net income over the same four quarters: −$391.6M, a −236.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$9.75.

  • Free cash flow in the twelve months to 30 June 2026: −$296.2M.

  • Shares outstanding: 44.7M.

  • Trailing P/E: −10.4×; forward P/E: −14.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • GRAIL, Inc. employs 910 people — $182K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Nov 2026

Data provided by Twelve Data

Peers

GRAL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
GRALGRAIL, Inc.$5.2B35
BLLNBillionToOne, Inc.$5.0B25
SHCSotera Health Co.$4.7B85
ADPTAdaptive Biotechnologies Corp.$4.6B76
RDNTRadNet, Inc.$5.9B42
CDNACareDx, Inc.$4.0B92
QGENQIAGEN NV$10.3B92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GRAIL, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GRAL news & analysis

GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript

Seeking Alpha · 10 Nov 2026neutral

GRAIL, Inc. CFO and Head of Corporate Development Aaron Freidin participated in the 2026 UBS Global Healthcare Conference on November 10, 2026. The excerpt identifies UBS analyst Douglas Schenkel as the conference call participant but provides no further discussion.

Why it matters — The transcript records a GRAIL executive’s participation in an investor conference, though the provided excerpt contains no substantive company updates.

GRAIL Q3 Earnings Call Ties FDA Review to Pricing and Sales Growth

Zacks Investment Research · 5 Nov 2026negative

GRAIL is lowering Galleri prices to encourage adoption ahead of an expected early 2027 FDA decision. Pricing pressure is weighing on revenue growth and margins.

Why it matters — The pricing strategy and its effects on growth and margins are relevant as investors track adoption ahead of the FDA decision.

Artisan Global Equity Fund Q3 2026 Portfolio Review

Seeking Alpha · 5 Nov 2026neutral

In Q3 2026, the Artisan Global Equity Fund underperformed the MSCI All Country World Index overall, while its health care stock selection significantly outperformed the benchmark’s health care holdings. The fund also made numerous portfolio changes and continued to focus on electrification, financials, and aerospace and defense.

Why it matters — The review mentions relative strength in health care, but does not identify GRAIL or describe a specific GRAIL-related portfolio action.

GRAIL, Inc. (GRAL) Q3 2026 Earnings Call Transcript

Seeking Alpha · 5 Nov 2026neutral

Seeking Alpha published a transcript of GRAIL, Inc.’s Q3 2026 earnings call.

Why it matters — The transcript provides GRAL watchers with the company’s remarks during its Q3 2026 earnings call.

What GRAIL (GRAL) Said on Its Q3 Earnings Call

MarketBeat · 5 Nov 2026neutral

GRAIL reported 4% revenue growth in the third quarter of 2026, as higher testing volumes were partly offset by lower prices. The company said it expects a U.S. regulatory decision on its Galleri cancer screening test by early in the first quarter of 2027.

Why it matters — The update highlights both recent revenue drivers and the expected timing of a regulatory decision for Galleri.

FAQ

Frequently asked questions about GRAL stock

What is the GRAL stock price forecast for 2026-2027?

The 10 Wall Street analysts covering GRAIL, Inc. have a median 12-month price target of $150, with estimates ranging from $100 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GRAL stock a buy right now?

Of the 10 analysts covering GRAIL, Inc., 5 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GRAIL, Inc. 35 out of 100 across roughly 4,600 US stocks as at 14 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GRAL?

As at 14 Nov 2026, GRAIL, Inc. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).

Will GRAL stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +29.6% from the last close, and Ticker Nerd's factor model ranks GRAIL, Inc. 35 out of 100 as at 14 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GRAL stock forecast for 2030?

No analyst covering GRAIL, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRAL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $100 to $175 over the next 12 months.

How has GRAL stock performed over the past year?

GRAIL, Inc. returned +39.2% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GRAIL, Inc. do?

GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services.

What is the latest news on GRAL?

The most recent item we track (Seeking Alpha, 10 Nov 2026): "GRAIL, Inc. (GRAL) Presents at 2026 UBS Global Healthcare Conference Transcript". GRAIL, Inc. CFO and Head of Corporate Development Aaron Freidin participated in the 2026 UBS Global Healthcare Conference on November 10, 2026. The excerpt identifies UBS analyst Douglas Schenkel as the conference call participant but provides no further discussion.

Company

About GRAIL, Inc.

GRAIL, Inc. is a commercial-stage healthcare company focused on multi-cancer early detection testing and services. Its core offering is Galleri, a blood-based screening test designed to detect multiple cancer types before symptoms appear, supporting earlier clinical evaluation and diagnosis. The company uses next-generation sequencing, machine learning, software, and automation to analyze biological signals associated with cancer and deliver screening insights through laboratory and service workflows. GRAIL serves healthcare providers and patients in the United States and international markets, with its work centered on cancer screening, diagnostic support, and related laboratory services. Headquartered in Menlo Park, California, GRAIL plays a notable role in the expanding field of liquid biopsy and genomic diagnostics, where it contributes to efforts aimed at improving early cancer detection and broadening access to advanced screening technologies.

CEO Dr. Joshua J. Ofman M.D., M.S.H.S · 910 employees · United States · https://grail.com